Manuele Furnari

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/681247/publications.pdf

Version: 2024-02-01

93	2,207	257450 24	233421 45
papers	citations	h-index	g-index

93	93	93	2136
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Applicability of Parameters for the Noninvasive Diagnosis of Esophageal Varices Needing Treatment to Hepatitis C Virusâ€“Cured Patients. Clinical Infectious Diseases, 2021, 72, 1862-1863.	5.8	1
2	Effects of SARS-CoV-2 emergency measures on high-risk lesions detection: a multicentre cross-sectional study. Gut, 2021, 70, 1241-1243.	12.1	8
3	Proactive Measures Aimed at Improving Appropriateness of Use of Proton Pump Inhibitors in Clinical Practice. Clinical Gastroenterology and Hepatology, 2021, 19, 410.	4.4	0
4	Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV. Annals of Hepatology, 2020, 19, 222-225.	1.5	5
5	Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease?. Nutrients, 2020, 12, 3363.	4.1	16
6	Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?. Cancers, 2020, 12, 1422.	3.7	41
7	Latest insights into the hot question of proton pump inhibitor safety â€“ a narrative review. Digestive and Liver Disease, 2020, 52, 842-852.	0.9	25
8	Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation. Digestive and Liver Disease, 2020, 52, 862-868.	0.9	11
9	Risk factors for bleeding following oesophageal band ligation: Providing further evidence to ameliorate clinical practice. Digestive and Liver Disease, 2020, 52, 792-793.	0.9	0
10	Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data . Clinical and Experimental Gastroenterology, 2020, Volume 13, 99-104.	2.3	14
11	Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. Expert Review of Clinical Pharmacology, 2020, 13, 437-449.	3.1	21
12	Course of oesophageal varices and performance of noninvasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease. European Journal of Clinical Investigation, 2020, 50, e13231.	3.4	8
13	Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohnâ€™s Disease. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 451-456.	0.9	21
14	Usefulness of Pep-Test for Laryngo-Pharyngeal Reflux: A Pilot Study in Primary Care. Korean Journal of Family Medicine, 2020, 41, 250-255.	1.2	7
15	The Role of Wireless Capsule Endoscopy (WCE) in the Detection of Occult Primary Neuroendocrine Tumors. Journal of Gastrointestinal and Liver Diseases, 2020, 26, 151-156.	0.9	14
16	New Devices for Endoscopic Treatments in Gastroenterology: A Narrative Review. Current Drug Metabolism, 2020, 21, 850-865.	1.2	1
17	A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients. American Journal of Gastroenterology, 2019, 114, 364-365.	0.4	1
18	Advancements in the use of manometry and impedance testing for esophageal functional disorders. Expert Review of Gastroenterology and Hepatology, 2019, 13, 425-435.	3.0	10

#	Article	IF	Citations
19	Hepatocellular Carcinoma Intermediate Stage Subclassification Systems: One, None, and One Hundred Thousand. Liver Cancer, 2019, 8, 524-526.	7.7	0
20	Regression of Fibrosis After Direct-acting AntiviralsÂTreatment of Patients withÂHepatitis C Virus Cirrhosis: Transposability to Nondecompensated Patients. Journal of Clinical and Experimental Hepatology, 2019, 9, 546.	0.9	0
21	Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals. European Journal of Clinical Investigation, 2019, 49, e13056.	3.4	30
22	The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin. Journal of Gastroenterology, 2019, 54, 261-270.	5.1	24
23	Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations. Digestive and Liver Disease, 2019, 51, 173-174.	0.9	2
24	Treatment of early stage chronic hepatitis C virus infection. Expert Review of Clinical Pharmacology, 2018, 11, 519-524.	3.1	6
25	Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients. Annals of Hepatology, 2018, 17, 830-835.	1.5	25
26	Proton pump inhibitors: use and misuse in the clinical setting. Expert Review of Clinical Pharmacology, 2018, 11, 1123-1134.	3.1	112
27	Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: The perfect storm. Liver International, 2018, 38, 2101-2101.	3.9	1
28	Sniffing out causes of gastrointestinal disorders: a review of volatile metabolomic biomarkers. Biomarkers in Medicine, 2018, 12, 1139-1148.	1.4	6
29	Highâ€resolution manometry is superior to endoscopy and radiology in assessing and grading sliding hiatal hernia: A comparison with surgical inÂvivo evaluation. United European Gastroenterology Journal, 2018, 6, 981-989.	3.8	55
30	A safety review of proton pump inhibitors to treat acid-related digestive diseases. Expert Opinion on Drug Safety, 2018, 17, 785-794.	2.4	24
31	NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis. Journal of Hepatology, 2018, 69, 972-973.	3.7	4
32	Outcome of Cytomegalovirus Colitis in Inflammatory Bowel Disease with Different Regimes of Ganciclovir. Middle East Journal of Digestive Diseases, 2018, 10, 220-229.	0.4	9
33	The appropriate use of proton-pump inhibitors. Minerva Medica, 2018, 109, 386-399.	0.9	46
34	Impairment of chemical clearance and mucosal integrity distinguishes hypersensitive esophagus from functional heartburn. Journal of Gastroenterology, 2017, 52, 444-451.	5.1	96
35	Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohnâ€™s disease. A study performed using the LÃ©mann Index. Digestive and Liver Disease, 2017, 49, 175-180.	0.9	25
36	Complexity and diversity of gastroesophageal reflux disease phenotypes. Minerva Gastroenterology, 2017, 63, 198-204.	0.5	1

#	Article	IF	Citations
37	Barrettâ€™s esophagus in 2016: From pathophysiology to treatment. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2016, 7, 190.	1.1	18
38	Tryciclic Antidepressants in Refractory GERD: Poorly Effective Drugs or Wrong Patients?. American Journal of Gastroenterology, 2016, 111, 1037-1038.	0.4	1
39	The sensory system of the esophagusâ€“â€“what do we know?. Annals of the New York Academy of Sciences, 2016, 1380, 91-103.	3.8	7
40	Microscopic Esophagitis, Baseline Impedance and Post-Reflux Swallow-Induced Peristaltic Wave in Functional Heartburn: Useful Diagnostic Tools. American Journal of Gastroenterology, 2016, 111, 1363-1364.	0.4	0
41	Interstitial lung disease in systemic sclerosis patients may benefit more from anti-reflux therapies than from immunosuppressants. Autoimmunity Reviews, 2016, 15, 1208-1209.	5.8	10
42	Fecal calprotectin in systemic sclerosis: Light and shade of a promising tool. Autoimmunity Reviews, 2016, 15, 1206-1207.	5.8	2
43	It is Time to Re-Think the Role of Small Intestinal Bacterial Overgrowth in IBS Patients. American Journal of Gastroenterology, 2016, 111, 1364.	0.4	2
44	Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. American Journal of Gastroenterology, 2016, 111, 1711-1717.	0.4	55
45	Current treatment options for esophageal diseases. Annals of the New York Academy of Sciences, 2016, 1381, 139-151.	3.8	11
46	Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1333-1341.	3.3	17
47	Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2016, 43, 1240-1241.	3.7	3
48	Caution About Overinterpretation of Number of Reflux Episodes in Reflux Monitoring for Refractory Gastroesophageal Reflux Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 1060.	4.4	3
49	Analyses of the Post-reflux Swallow-induced Peristaltic Wave Index and Nocturnal Baseline Impedance Parameters Increase the Diagnostic Yield of Impedance-pH Monitoring of Patients With Reflux Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 40-46.	4.4	222
50	Esophagogastric junction morphology assessment by high resolution manometry in obese patients candidate to bariatric surgery. International Journal of Surgery, 2016, 28, S109-S113.	2.7	21
51	Degree of colonic distension: intrapatient comparison between CT colonography and CT with water enema. Clinical Imaging, 2016, 40, 425-430.	1.5	3
52	Extending landscape of volatile metabolites as novel diagnostic biomarkers of inflammatory bowel disease â€“ a review. Scandinavian Journal of Gastroenterology, 2016, 51, 385-392.	1.5	14
53	Comparison of computed tomography and magnetic resonance imaging in the discrimination of intraperitoneal and extraperitoneal rectal cancer: initial experience. Clinical Imaging, 2016, 40, 57-62.	1.5	3
54	Breath Tests to Assess Alcoholic Liver Disease. Reviews on Recent Clinical Trials, 2016, 11, 185-190.	0.8	2

#	Article	IF	Citations
55	Pre-operative clinical and instrumental factors as antireflux surgery outcome predictors. World Journal of Gastrointestinal Surgery, 2016, 8, 719.	1.5	9
56	Esophageal testing: What we have so far. World Journal of Gastrointestinal Pathophysiology, 2016, 7, 72.	1.0	26
57	Esophagogastric junction morphology is associated with a positive impedanceâ€<scp>pH</scp> monitoring in patients with <scp>GERD</scp>. Neurogastroenterology and Motility, 2015, 27, 1175-1182.	3.0	91
58	Esophagogastric junction contractility for clinical assessment in patients with <scp>GERD</scp>: a real added value?. Neurogastroenterology and Motility, 2015, 27, 1423-1431.	3.0	85
59	Gastric and masticatory performances in fullâ€arch immediate loading rehabilitated patients. Journal of Oral Rehabilitation, 2015, 42, 663-669.	3.0	3
60	A More In-depth Evaluation of Impedance-pH Could Assist in Distinguishing Reflux-related From Reflux-unrelated Heartburn. Journal of Neurogastroenterology and Motility, 2015, 21, 621-622.	2.4	1
61	Optimal management of constipation associated with irritable bowel syndrome. Therapeutics and Clinical Risk Management, 2015, 11, 691.	2.0	11
62	Hepatocellular Carcinoma Is the Most Frequent Final Diagnosis of Focal Liver Lesions Identified in a Cross-Sectional Evaluation of Patients with Chronic Liver Disease in Saudi Arabia. Journal of Cancer Research, 2015, 2015, 1-4.	0.7	1
63	Association Between Baseline Impedance Values and Response Proton Pump Inhibitors in Patients With Heartburn. Clinical Gastroenterology and Hepatology, 2015, 13, 1082-1088.e1.	4.4	121
64	Measurement of oro-caecal transit time by magnetic resonance imaging. European Radiology, 2015, 25, 1579-1587.	4.5	13
65	Incidental physiological sliding hiatal hernia: a single center comparison study between CT with water enema and CT colonography. Radiologia Medica, 2015, 120, 683-689.	7.7	3
66	Mo1128 Are Baseline Impedance Levels Assessed During Esophageal Impedance Manometry Helpful in Discriminating Patients With Gastroesophageal Reflux Disease From Those Without? A Pilot Study. Gastroenterology, 2015, 148, S-614-S-615.	1.3	0
67	Manually calculated oesophageal bolus clearance time increases in parallel with reflux severity at impedance-pH monitoring. Digestive and Liver Disease, 2015, 47, 1027-1032.	0.9	12
68	Data on Symptom Association Analysis in Patients Undergoing Endoscopic Therapy Is Useful to Better Define a Successful Therapeutic Approach. American Journal of Gastroenterology, 2015, 110, 1621.	0.4	2
69	Use of Liver Breath Tests to Assess Severity of Nonalcoholic Fatty Liver Disease. Reviews on Recent Clinical Trials, 2015, 9, 178-184.	0.8	2
70	Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. Journal of Neurogastroenterology and Motility, 2014, 20, 129-130.	2.4	2
71	Esophageal biopsies in the management of GERD: complementary tool for many but not for all. Human Pathology, 2014, 45, 2512-2513.	2.0	3
72	Proton pump inhibitor responders who are not confirmed as <scp>GERD</scp> patients with impedance and pH monitoring: who are they?. Neurogastroenterology and Motility, 2014, 26, 28-35.	3.0	73

#	Article	IF	Citations
73	Letter: treatment for small intestinal bacterial overgrowth â€“ where are we now?. Alimentary Pharmacology and Therapeutics, 2014, 39, 442-442.	3.7	2
74	Not all anti-reflux treatment failures are due to persistence of abnormal esophageal acid exposure. Surgical Endoscopy and Other Interventional Techniques, 2014, 28, 1382-1383.	2.4	1
75	Reflux pattern and role of impedanceâ€pH variables in predicting PPI response in patients with suspected GERDâ€related chronic cough. Alimentary Pharmacology and Therapeutics, 2014, 40, 966-973.	3.7	63
76	Gastrointestinal involvement in systemic sclerosis. Presse Medicale, 2014, 43, e279-e291.	1.9	59
77	The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders. Journal of Gastroenterology, 2014, 49, 1362-1363.	5.1	1
78	Tu1805 Different Accuracy of Various Impedance-pH Normal Values in Diagnosing GERD in Patients With Proven Reflux Disease. Gastroenterology, 2013, 144, S-850-S-851.	1.3	0
79	Tu1771 Impedance-pH Explores With More Accuracy Than pH-Metry Alone the Relationship Between Aspiration of Gastric Contents and Gastroesophageal Reflux in Patients With Idiopathic Pulmonary Fibrosis. Gastroenterology, 2013, 144, S-840-S-841.	1.3	0
80	Lactulose Breath Test to Assess Oro-cecal Transit Delay and Estimate Esophageal Dysmotility in Scleroderma Patients. Seminars in Arthritis and Rheumatism, 2013, 42, 522-529.	3.4	29
81	Feasibility of the Cutâ€andâ€Push Method for Removing Largeâ€Caliber Soft Percutaneous Endoscopic Gastrostomy Devices. Nutrition in Clinical Practice, 2013, 28, 490-492.	2.4	17
82	Gastrointestinal motility disorder assessment in systemic sclerosis. Rheumatology, 2013, 52, 1095-1100.	1.9	87
83	Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. European Respiratory Journal, 2013, 42, 1322-1331.	6.7	194
84	A Comparison Between Lactose Breath Test and Quick Test on Duodenal Biopsies for Diagnosing Lactase Deficiency in Patients With Self-reported Lactose Intolerance. Journal of Clinical Gastroenterology, 2013, 47, 148-152.	2.2	29
85	Alginate controls heartburn in patients with erosive and nonerosive reflux disease. World Journal of Gastroenterology, 2012, 18, 4371.	3.3	59
86	Reassessment of the role of methane production between irritable bowel syndrome and functional constipation. Journal of Gastrointestinal and Liver Diseases, 2012, 21, 157-63.	0.9	28
87	Full-Dose Peginterferon Alfa-2a and Low-Dose Ribavirin Treatment of Genotypes 1 and 4 Chronic Hepatitis CPatients With End-Stage Renal Disease. Clinical Gastroenterology and Hepatology, 2011, 9, 1004.	4.4	2
88	Gastroesophageal Reflux is More Relevant Than Motor Dysfunction in Provoking Non-Cardiac Chest Pain. Gastroenterology, 2011, 140, S-251-S-252.	1.3	0
89	Overweight is a risk factor for both erosive and non-erosive reflux disease. Digestive and Liver Disease, 2011, 43, 940-945.	0.9	52
90	Impedance-pH Monitoring Increases the Diagnostic Yield in Endoscopic Negative Patients With Non-Cardiac Chest Pain. Gastroenterology, 2011, 140, S-247-S-248.	1.3	0

#	Article	IF	Citations
91	The Differing Role of Overweight Among the Various Subgroups of Non-Erosive Reflux Disease. Gastroenterology, 2011, 140, S-627.	1.3	0
92	Can We Estimate Oro-Cecal Transit Time Using Magnetic Resonance Imaging (MRI)? A Comparison With Hydrogen Breath Test (H2-BT) in Healthy Volunteers. Gastroenterology, 2011, 140, S-446.	1.3	0
93	Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. Alimentary Pharmacology and Therapeutics, 2010, 32, 1000-1006.	3.7	62